Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 4
1990 2
1991 1
1992 3
1993 2
1994 2
1996 1
1997 2
1998 2
2000 1
2001 1
2004 1
2006 2
2007 1
2008 3
2009 3
2010 2
2011 6
2012 5
2013 6
2014 1
2015 4
2016 4
2018 4
2019 3
2020 2
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection.
Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium. Musvosvi M, et al. Nat Med. 2023 Jan;29(1):258-269. doi: 10.1038/s41591-022-02110-9. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604540 Free PMC article.
Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ. Gupta R, et al. Among authors: geiter lj. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Int J Tuberc Lung Dis. 2016. PMID: 28240570 Review.
Delamanid for Extensively Drug-Resistant Tuberculosis.
Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H. Gupta R, et al. Among authors: geiter lj. N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. N Engl J Med. 2015. PMID: 26176402 Free article. Clinical Trial. No abstract available.
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, Kim SK, Kim SJ, Kang YS, Kim TH, Mok J, Byun MK, Park HJ, Joh JS, Park YB, Lim HS, Choi H, Lee SH, Kim H, Yang J, Kim H, Shen X, Alsultan A, Cho I, Geiter L, Shim TS. Kim JS, et al. Among authors: geiter l. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0168421. doi: 10.1128/AAC.01684-21. Epub 2021 Dec 6. Antimicrob Agents Chemother. 2022. PMID: 34871098 Free PMC article. Clinical Trial.
Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis.
Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, Pyne-Mercier L, Keshavjee S, Varaine F; Research Excellence to Stop TB Resistance (RESIST-TB); Critical Path to TB Drug Regimens' Access and Appropriate Use Workgroup. Horsburgh CR Jr, et al. Int J Tuberc Lung Dis. 2013 Feb;17(2):146-52. doi: 10.5588/ijtld.12.0017. Epub 2012 Dec 4. Int J Tuberc Lung Dis. 2013. PMID: 23211610 Review.
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.
Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A, Wallis RS, Sebe M, Mhimbira FA, Mbeya B, Rassool M, Geiter L, Cho YL, Heinrich N. Dierig A, et al. Among authors: geiter l. Trials. 2023 Jun 6;24(1):382. doi: 10.1186/s13063-023-07354-5. Trials. 2023. PMID: 37280643 Free PMC article. Clinical Trial.
Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Gler MT, et al. Among authors: geiter lj. N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433. N Engl J Med. 2012. PMID: 22670901 Free article. Clinical Trial.
Metabolite changes in blood predict the onset of tuberculosis.
Weiner J 3rd, Maertzdorf J, Sutherland JS, Duffy FJ, Thompson E, Suliman S, McEwen G, Thiel B, Parida SK, Zyla J, Hanekom WA, Mohney RP, Boom WH, Mayanja-Kizza H, Howe R, Dockrell HM, Ottenhoff THM, Scriba TJ, Zak DE, Walzl G, Kaufmann SHE; GC6-74 consortium. Weiner J 3rd, et al. Nat Commun. 2018 Dec 6;9(1):5208. doi: 10.1038/s41467-018-07635-7. Nat Commun. 2018. PMID: 30523338 Free PMC article.
Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis.
Suliman S, Thompson EG, Sutherland J, Weiner J 3rd, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell HM, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SHE, Zak DE, Walzl G; GC6-74 cohort study team, The ACS cohort study team. Suliman S, et al. Am J Respir Crit Care Med. 2018 May 1;197(9):1198-1208. doi: 10.1164/rccm.201711-2340OC. Am J Respir Crit Care Med. 2018. PMID: 29624071 Free PMC article.
64 results